In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Europe:


Bettina Ryll: Stockholm School of Economics, Institute for Research; Founder, Melanoma Patient Network Europe.


Kjetil Taskén: Head of the Institute for Cancer Research, Oslo University Hospital; Professor, University of Oslo; Coordinator, PRIME-ROSE.


Anni Lepland: Head of Personalized Medicine in Oncology, Estonian Cancer Network.

They explore how Europe’s new Joint Action can accelerate equitable precision oncology, what PRIME-ROSE has learned from aggregating data across national pragmatic trials, and why a distributed, bottom-up model with strong patient involvement and industry collaboration is key to scaling access and evidence generation across member states.

Key Topics:


EU Joint Action: Governmental collaboration, precision prevention, diagnosis, and treatment, precision follow-up.


PRIME-ROSE Collaboration: Data sharing agreements, aggregated cohorts, common biomarker definitions, and monthly alignment.


Patient Need First: Options after standard care, access to molecular profiling, pragmatic protocols, and learning from each case.


Widening Country Gaps: Workforce shortages, national coordination, digital tools, and equitable access to innovative drugs.


Industry and Access: Single point of entry for drugs, managed entry agreements, off-label registries, and scaling trials across Europe.

Opinions expressed are those of the speakers.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/">Duane Schulthess</a> speaks with three leaders advancing precision cancer medicine implementation in Europe:
<ul data-start="178" data-end="502">
<li data-start="178" data-end="287">
<a href="https://www.linkedin.com/in/bettinaryll/">Bettina Ryll</a>: <a href="https://www.linkedin.com/school/stockholm-school-of-economics/">Stockholm School of Economics</a>, Institute for Research; Founder, <a href="https://www.linkedin.com/company/mpneurope/">Melanoma Patient Network Europe</a>.
</li>
<li data-start="288" data-end="412">
<a href="https://www.linkedin.com/in/kjetil-tasken-06a261b/">Kjetil Task&eacute;n</a>: Head of the Institute for Cancer Research, <a href="https://www.linkedin.com/company/oslo-universitetssykehus/">Oslo University Hospital</a>; Professor, <a href="https://www.linkedin.com/school/amarjyot-med-college/about/">University of Oslo</a>; Coordinator, <a href="https://www.linkedin.com/company/prime-rose/">PRIME-ROSE</a>.
</li>
<li data-start="413" data-end="502">
<a href="https://www.linkedin.com/in/anni-lepland-898165242/?originalSubdomain=ee">Anni Lepland</a>: Head of Personalized Medicine in Oncology, <a href="https://www.linkedin.com/company/estonian-cancer-network-estcan/">Estonian Cancer Network</a>.
</li>
</ul>
They explore how Europe&rsquo;s new Joint Action can accelerate equitable precision oncology, what <a href="https://www.linkedin.com/company/prime-rose/">PRIME-ROSE </a>has learned from aggregating data across national pragmatic trials, and why a distributed, bottom-up model with strong patient involvement and industry collaboration is key to scaling access and evidence generation across member states.
Key Topics:
<ul data-start="862" data-end="1502">
<li data-start="862" data-end="980">
EU Joint Action: Governmental collaboration, precision prevention, diagnosis, and treatment, precision follow-up.
</li>
<li data-start="981" data-end="1106">
PRIME-ROSE Collaboration: Data sharing agreements, aggregated cohorts, common biomarker definitions, and monthly alignment.
</li>
<li data-start="1107" data-end="1238">
Patient Need First: Options after standard care, access to molecular profiling, pragmatic protocols, and learning from each case.
</li>
<li data-start="1239" data-end="1364">
Widening Country Gaps: Workforce shortages, national coordination, digital tools, and equitable access to innovative drugs.
</li>
<li data-start="1365" data-end="1502">
Industry and Access: Single point of entry for drugs, managed entry agreements, off-label registries, and scaling trials across Europe.
</li>
</ul>
Opinions expressed are those of the speakers.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Advertisement